---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-018774"
form_type: "8-K"
ticker: "JANX"
cik: "0001817713"
company_name: "Janux Therapeutics, Inc."
filed_at: "2022-09-22T23:59:59+00:00"
generated_at: "2026-06-23T08:04:38.187617+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Janux appoints Winston Kung to board; Stefan Heller resigns

## Summary
- Winston Kung appointed as Class I director, term expiring at 2025 annual meeting, effective Sept 21, 2022.
- Stefan Heller resigned from board effective same day; not due to any disagreement with the company.
- Kung receives $40k annual cash retainer (board) + $4k (committee) and stock options: 30k shares (3-yr vest) and 9,375 shares (1-yr vest).
- Kung is CFO/COO at PMV Pharma; prior VP Business Development at Celgene and roles at Citigroup and Amgen.
- Changes effective immediately per press release dated September 22, 2022.

## SEC filing metadata
- accession: 0000950170-22-018774
- form_type: 8-K
- ticker: JANX
- cik: 0001817713
- company_name: Janux Therapeutics, Inc.
- filed_at: 2022-09-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817713/000095017022018774/0000950170-22-018774-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817713/000095017022018774/janx-20220921.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-018774
- JSON: https://secwatch.observer/filing/0000950170-22-018774.json
- Plain text: https://secwatch.observer/filing/0000950170-22-018774.txt

## Key facts
- Executive change
  Stefan Heller resigned as Director at Janux Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: Also on September 21, 2022, Stefan Heller, Ph.D., resigned as a member of the Board effective as of such date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817713/000095017022018774/0000950170-22-018774-index.htm
- Executive change
  Winston Kung was appointed as Class I director at Janux Therapeutics, Inc..
  - Action: appointed
  - Role: Class I director
  source text: On September 21, 2022, the Board of Directors (the “Board”) of Janux Therapeutics, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Governance Committee”), appointed Winston Kung as a Class I director of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817713/000095017022018774/0000950170-22-018774-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.